Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tegafur/gimeracil/oteracil plus camrelizumab for EBV-DNA residual locally advanced nasopharyngeal carcinoma
ChiCTR2500098668Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Xiamen University
- Start
- Mar 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tegafur + gimeracil + oteracil and camrelizumab in nasopharyngeal carcinoma (NPC), sponsored by First Affiliated Hospital of Xiamen University. Primary endpoint: Progression-free survival time. Started Mar 2025; status: recruiting.
02
Drugs
tegafur + gimeracil + oteracilcamrelizumab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR2500098668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500098668.